p53 and WAF1 polymorphisms in Jewish-Israeli women with epithelial ovarian cancer and its association with BRCA mutations
Open Access
- 1 July 2000
- journal article
- Published by Wiley in BJOG: An International Journal of Obstetrics and Gynaecology
- Vol. 107 (7) , 849-854
- https://doi.org/10.1111/j.1471-0528.2000.tb11082.x
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoterOncogene, 1999
- BRCA1 physically associates with p53 and stimulates its transcriptional activityOncogene, 1998
- High Frequency of BRCA1 and BRCA2 Germline Mutations in Ashkenazi Jewish Ovarian Cancer Patients, Regardless of Family HistoryGynecologic Oncology, 1997
- Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPlNature, 1997
- Partial rescue of Brca15–6 early embryonic lethality by p53 or p21 null mutationNature Genetics, 1997
- BRCAGenes — Bookmaking, Fortunetelling, and Medical CareNew England Journal of Medicine, 1997
- The Risk of Cancer Associated with Specific Mutations ofBRCA1andBRCA2among Ashkenazi JewsNew England Journal of Medicine, 1997
- High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian CancerPublished by American Medical Association (AMA) ,1996
- The Tumor Suppressor Gene Brca1 Is Required for Embryonic Cellular Proliferation in the MouseCell, 1996
- Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locusNature Genetics, 1996